These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28044936)

  • 1. Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward.
    Colletti M; Paolo VD; Galardi A; Milano GM; Mastronuzzi A; Locatelli F; Di Giannatale A
    Anticancer Agents Med Chem; 2017; 17(10):1328-1343. PubMed ID: 28044936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges.
    Zhang M; Zang X; Wang M; Li Z; Qiao M; Hu H; Chen D
    J Mater Chem B; 2019 Apr; 7(15):2421-2433. PubMed ID: 32255119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in targeted nanomedicine as promising antitumor therapeutics.
    Hejmady S; Pradhan R; Alexander A; Agrawal M; Singhvi G; Gorain B; Tiwari S; Kesharwani P; Dubey SK
    Drug Discov Today; 2020 Dec; 25(12):2227-2244. PubMed ID: 33011342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-sensitive nano-systems for drug delivery in cancer therapy.
    Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
    Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smart Nanocarriers for Targeted Cancer Therapy.
    Martinelli C
    Anticancer Agents Med Chem; 2021; 21(5):546-557. PubMed ID: 32560615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges.
    Syn NL; Wang L; Chow EK; Lim CT; Goh BC
    Trends Biotechnol; 2017 Jul; 35(7):665-676. PubMed ID: 28365132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer therapy based on extracellular vesicles as drug delivery vehicles.
    Cabeza L; Perazzoli G; Peña M; Cepero A; Luque C; Melguizo C; Prados J
    J Control Release; 2020 Nov; 327():296-315. PubMed ID: 32814093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting liposomes toward novel pediatric anticancer therapeutics.
    Federman N; Denny CT
    Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prodrug strategy for cancer cell-specific targeting: A recent overview.
    Zhang X; Li X; You Q; Zhang X
    Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.
    Jang SC; Kim OY; Yoon CM; Choi DS; Roh TY; Park J; Nilsson J; Lötvall J; Kim YK; Gho YS
    ACS Nano; 2013 Sep; 7(9):7698-710. PubMed ID: 24004438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the past, present, and future of cancer nanomedicine.
    Youn YS; Bae YH
    Adv Drug Deliv Rev; 2018 May; 130():3-11. PubMed ID: 29778902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
    Greish K
    Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmable nanomedicine: synergistic and sequential drug delivery systems.
    Pacardo DB; Ligler FS; Gu Z
    Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.
    Kumar S; Mokhtari RB; Yeger H; Baruchel S
    Expert Opin Drug Discov; 2012 Nov; 7(11):1093-106. PubMed ID: 22998522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Opportunities in Neuroblastoma Using Nanotechnology.
    Rodríguez-Nogales C; Noguera R; Couvreur P; Blanco-Prieto MJ
    J Pharmacol Exp Ther; 2019 Sep; 370(3):625-635. PubMed ID: 30635473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Strategies in Cancer Nanomedicine.
    Tong R; Kohane DS
    Annu Rev Pharmacol Toxicol; 2016; 56():41-57. PubMed ID: 26514197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines in the future of pediatric therapy.
    Sosnik A; Carcaboso AM
    Adv Drug Deliv Rev; 2014 Jun; 73():140-61. PubMed ID: 24819219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.